| Literature DB >> 31426402 |
Wei Li1,2, Qian Liu1,2, Shanren Li1,2, Yongbiao Zheng3,4,5.
Abstract
Termitomyces albuminosus is the symbiotic edible mushroom of termites and cannot be artificially cultivated at present. In the project of exploring its pharmaceutical metabolites by microbial fermentation, four new selinane type sesquiterpenoids-teucdiol C (1), D (2), E (3), and F (4), together with two known sesquiterpenoids teucdiol B (5) and epi-guaidiol A (6)-were obtained from its fermented broth of T. albuminosus. Their structures were elucidated by the analysis of NMR data, HR Q-TOF MS spectral data, CD, IR, UV, and single crystal X-ray diffraction. Epi-guaidiol A showed obvious anti-acetylcholinesterase activity in a dose-dependent manner. The experimental results displayed that T. albuminosus possess the pharmaceutical potential for Alzheimer's disease, and it was an effective way to dig new pharmaceutical agent of T. albuminosus with the microbial fermentation technique.Entities:
Keywords: Termitomyces albuminosus; anti-acetylcholinesterase; microbial fermentation; selinane; sesquiterpenoids
Mesh:
Substances:
Year: 2019 PMID: 31426402 PMCID: PMC6719985 DOI: 10.3390/molecules24162980
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
1H-NMR spectral data of 1–6.
| No. | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| 1α | 1.44 (o, 1H) 1 | 1.45 (o, 1H) | 1.42 (o, 1H) | 1.37 (o, 1H) | 1.74 (o,1H) | 2.04 (m, 1H) |
| 1β | 1.11 (o, 1H) | 1.10 (o, 1H) | 1.10 (o, 1H) | 1.13 (dd, | 1.35–1.29 (o,1H) | |
| 2α | 1.60 (o, 1H) | 1.56 (o, 1H) | 1.58 (o, 1H) | 1.53 (o, 1H) | 2.31 (dt, | 1.67–1.69 (o, 2H) |
| 2β | 1.65 (o, 1H) | 1.63 (o, 1H) | 1.62 (o, 1H) | 1.40 (o, 1H) | 1.40 (o, 1H) | |
| 3α | 1.79 (o, 1H) | 1.77 (o, 1H) | 1.77 (m, 1H) | 1.76 (o, 1H) | 1.74 (o, 1H) | 1.93 (m, 1H) |
| 3β | 1.40 (o, 1H) | 1.42 (m, 1H) | 1.38 (m, 1H) | 1.44 (o, 1H) | 1.35–1.29 (o, 1H) | 1.64 (o, 1H) |
| 5 | 1.26 (dd, | 1.27 (o, 1H) | 1.30 (o, 1H) | 1.62 (o, 1H) | 1.23 (dd, | 2.58 (m, 1H) |
| 6α | 1.71 (o, 1H) | 1.80 (o, 1H) | 1.34 (o, 1H) | 1.46 (o, 1H | 1.60–1.54 (o, 2H) | 1.76 (o, 1H) |
| 6β | 2.91 (d, | 2.99 (m, 1H) | 2.24 (dd, | 1.97 (m, 1H)) | 1.51 (o, 1H) | |
| 7 | 1.91 (m, 1H) | 2.15 (td, | ||||
| 8α | 2.04 (m, 1H) | 2.09 (m, 1H) | 1.47 (m, 1H) | 1.65 (o, 1H) | 1.67 (m, 1H) | 1.63 (o, 1H) |
| 8β | 2.67 (m, 1H) | 2.68 (m, 1H) | 1.84 (m, 1H) | 1.81 (o, 1H) | 1.40 (o, 1H) | |
| 9α | 1.49 (o, 1H) | 1.52 (o, 1H) | 1.26 (o, 1H) | 1.56 (o, 1H) | 1.04 (dd, | 1.83 (o, 1H) |
| 9β | 1.20 (m, 1H) | 1.24 (o, 1H) | 1.21 (td, | 1.20 (m, 1H) | 1.56 (o, 1H) | |
| 11 | 2.02 (m, 1H) | |||||
| 12 | 4.10 (s, 2H) | 4.20 (s, 2H) | 3.76 (m, 2H) | 3.48 (d, | 5.10 (s, 1H) | 4.66 (m, 1H) |
| 5.01 (s, 1H) | 4.59 (m, 1H) | |||||
| 13 | 1.80 (s, 3H) | 4.24 (s, 2H) | 1.04 (d, | 1.22 (s, 3H) | 1.82 (s, 3H) | 1.71 (s, 3H) |
| 14α | 1.14 (s, 1H) | 1.12 (s, 3H) | 1.09 (s, 3H) | 1.08 (s, 3H) | 1.09 (s, 3H) | 1.14 (s, 3H) |
| 15α | 1.04 (s, 1H) | 1.04 (s, 3H) | 0.98 (s, 3H) | 0.94 (s, 3H) | 0.99 (s, 3H) | 1.21 (s, 3H) |
1 Recorded at 500 MHz in MeOD; λ in ppm, J in Hz.
13C-NMR spectral data of 1–6.
| No. | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| 1 | 42.3t 1 | 42.2t | 42.0t | 43.3t | 43.7t | 53.6d |
| 2 | 21.2t | 21.3t | 21.3t | 21.4t | 32.3t | 40.7t |
| 3 | 44.0t | 44.2t | 44.0t | 44.5t | 43.7t | 42.7t |
| 4 | 73.1s | 73.20s | 72.8s | 73.5s | 72.8s | 75.7s |
| 5 | 56.5d | 56.7d | 51.9d | 50.5d | 52.2d | 52.9d |
| 6 | 26.4t | 26.2t | 32.9t | 22.1t | 21.2t | 31.7t |
| 7 | 138.2s | 130.3s | 76.7s | 38.7d | 76.0s | 48.6d |
| 8 | 26.5t | 27.0t | 33.3t | 21.7t | 33.3t | 33.0t |
| 9 | 47.1t | 46.9t | 42.7t | 43.5t | 42.2t | 26.47t |
| 10 | 36.1s | 36.2s | 35.9s | 35.5s | 36.0s | 82.0s |
| 11 | 125.9s | 144.1s | 37.1d | 77.4s | 148.1s | 153.7s |
| 12 | 63.4t | 60.29t | 65.3t | 69.8t | 114.0t | 108.5t |
| 13 | 16.7q | 60.31t | 12.1q | 23.6q | 19.2q | 20.5q |
| 14 | 22.3q | 22.3q | 22.5q | 22.2q | 22.7q | 24.0q |
| 15 | 18.8q | 18.9q | 19.3q | 19.7q | 19.5q | 26.52q |
1 Recorded at 500 MHz in MeOD; λ in ppm, J in Hz.
Figure 1The chemistry structures of compounds 1–6.
Figure 2The crystal form of compound 1.
The inhibition rate of compound 6 against acetylcholinesterase activity.
| Concentration of Compound 6 (mM) | Inhibition Rate (%) |
|---|---|
| 2.10 | 56.2 ± 0.8 1 |
| 1.57 | 53.4 ± 4.0 |
| 1.05 | 44.5 ± 3.6 |
| 0.52 | 33.6 ± 3.8 |
| Positive control | 94.6 ± 1.5 |
| Vehicle | 6.40 ± 1.9 |
1 The value is the average for three replicate and standard deviation.